NeoGenomics launches NGS assay for AML

Researchers discover gene that could help improve treatment decisions in childhood leukemia

A new type of cancer cell that “warrants urgent investigation” has been discovered in childhood leukaemia, and could impact clinical care. Research into new or repurposed treatments that target this new cell type could give hope to children and families worldwide.

November 14, 2025

Vol.51 No.42

Drugs & Targets

FDA approves Komzifti for r/r NPM1-mutated AML

FDA has granted full approval of Komzifti (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Komzifti is the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated AML, a devastating blood cancer with limited treatment options.

November 14, 2025

Vol.51 No.42

Clinical Roundup

DNA sequencing tool reveals hidden mutations that can drive cancer

Researchers have refined a powerful DNA sequencing tool that can uncover hidden mutations that occur naturally in our bodies as we age. In the largest study to date, they have used the tool to provide insights into the earliest steps of cancer development and the role of mutations in healthy tissue.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Study assesses cancers in children exposed to medical imaging

Ten percent of pediatric blood and bone marrow cancers may have stemmed from radiation exposure, according to a study led by UC San Francisco and UC Davis.

September 26, 2025

Vol.51 No.35

Drugs & Targets

FDA grants Fast Track designation for CER-1236 in AML

FDA has granted Fast Track designation to CER-1236 for Acute Myeloid Leukemia. CER-1236 is a therapy that engineers a cancer patient’s own T-cell therapeutics that deploy phagocytic mechanisms alongside the array of built-in target cell destroying mechanisms used by T-cells.

September 12, 2025

Vol.51 No.33